Regulatory Perspectives on QbD, RBQM, and RBM in Pharma and Clinical Research
Why are pharma and clinical trial leaders doubling down on QbD, RBQM, and RBM in 2025? Because “compliance” is no longer enough, today, regulators expect quality, risk-awareness, and strategy to be embedded from the very beginning. From decentralized trials to AI-driven insights, the pace of change is rapid—and so are the expectations from regulators like […]
Regulatory Perspectives on QbD, RBQM, and RBM in Pharma and Clinical Research Read More »